{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "AKBA",
  "name": "Akebia Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/AKBA/",
  "json_url": "https://orbyd.app/dossiers/AKBA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "VOICE outcomes win (USRC trial stopped early, June 2026) de-risked Vafseo's dialysis-anemia case, but the tape bled to ~$1.22, only ~48% above the $0.82 low and still fading; the late-July/early-August Q2 print is the binary — commercial-ramp confirmation plus a possible DaVita signal vs another show-me quarter into the 2027 bundle cliff.",
  "invalidation_trigger": "A weekly close below $1.15 loses the post-VOICE base and reopens the $0.82 52-week low; a Q2 print (late-July/early-August 2026) showing Vafseo revenue decelerating with another guidance cut, or the theme flipping to saturated on the 2027 bundle cliff, confirms the value-trap read.",
  "catalyst_date": null,
  "outcome": "INVALIDATED",
  "outcome_date": "2026-08-06",
  "invalidation_fired": true,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q1 2026: Vafseo net rev $15.8M (+32% YoY), ~7,500 patients (+60% QoQ), ~1,025 prescribers; total rev fell -6.6% YoY on Auryxia erosion. Cash $162.6M, ≥2yr runway. HC Wainwright Buy $6 PT (2026-07-01).",
    "Micro-cap ~$377M, unprofitable (P/E ~-18), thin liquidity — catalyst/flow-driven, not sector-beta. No momentum confirmation at current price; probe-only until structure reclaims.",
    "Q2 2026 earnings imminent, after close — vendors split on exact date (TipRanks lists 2026-07-30, stockanalysis lists 2026-08-06); commercial-ramp binary, avoid fresh entries into the print.",
    "VOICE interim (announced 2026-06-30, data through 2026-06-01): 2,116-pt USRC trial stopped early for success; non-inferiority + superiority, win odds 1.16 (p=0.0016), hospitalizations IRR 0.90, mortality neutral. Positive readout did NOT re-rate the stock, which has since faded toward the $0.82 low.",
    "Price decay: ~$1.40 mid-July → ~$1.22 (2026-07-24). 52-week range $0.823–$4.010, market cap ~$327M. No momentum confirmation — probe-only until structure reclaims ~$1.60 on volume.",
    "Seeking Alpha downgrade 2026-07-14: 'show-me story' — Vafseo adherence ~86% and +60% QoQ patients, but profitability distant; 45–55% discount to peers reflects execution risk. DaVita adoption in 2H26 named as the key upside catalyst.",
    "Guide trimmed: 2026 revenue estimate cut $222.5M → $206.6M; FY loss widened ~$0.056 → ~$0.17/sh. Q1 2026: Vafseo net rev $15.8M (+32% YoY), ~7,500 patients, ~1,025 prescribers; total rev $53.5M (-6.6% YoY) on Auryxia erosion; net loss $9.1M; cash $162.6M, ~2yr runway.",
    "2027 ESRD PPS bundle entry + TDAPA expiry is the structural reimbursement overhang capping any re-rate — the core bear pillar. Analyst consensus Strong Buy, avg PT ~$4.20; HC Wainwright Buy $6 (2026-07-01)."
  ],
  "body_markdown": "## Current Thesis\nA single-asset renal pharma whose science de-risked while its tape kept bleeding. On 2026-06-30 the U.S. Renal Care-sponsored VOICE outcomes trial was stopped early for success: Vafseo (vadadustat), dosed three-times-weekly in hemodialysis, met non-inferiority and statistical superiority versus standard ESAs on a composite of mortality and hospitalization. The narrative leg an investor buys here is conversion — independent outcomes data pushing Vafseo from \"another anemia option\" toward a protocol-preferred agent inside the large dialysis organizations, with DaVita adoption in 2H26 flagged as the single biggest swing factor. The problem is the response: price did not re-rate on the readout and has since faded from ~$1.40 in mid-July to ~$1.22 (2026-07-24), grinding toward the $0.82 52-week low. A Seeking Alpha downgrade on 2026-07-14 reframed this as a show-me story, and the 2026 revenue guide was trimmed. The late-July/early-August Q2 print is the next binary that either wakes the tape up or confirms neglect.\n\n## Bull Case\n- VOICE interim (data through 2026-06-01, announced 2026-06-30): 2,116-patient, independent, pragmatic outcomes trial stopped early; win odds 1.16 (95% CI 1.06–1.28, p=0.0016), hospitalizations 1.11 vs 1.23 per patient-year (IRR 0.90, 95% CI 0.824–0.988), mortality neutral (8.77% vs 8.78% per 100 patient-years). This is the class of data dialysis organizations cite to rewrite anemia protocols.\n- Q1 2026 (reported 2026-05-07): Vafseo net revenue $15.8M, +32% YoY vs $12.0M and the highest quarter to date; ~7,500 patients (+60% QoQ) across ~1,025 prescribers (+28% QoQ); adherence ~86% on the observed-dosing protocol.\n- DaVita adoption flagged as the key 2H26 upside catalyst (Seeking Alpha, 2026-07-14) — the largest U.S. dialysis operator; a protocol win there would step-change the patient base.\n- FY2025 revenue $236.2M, +47% vs $160.2M — the consolidated top line grew even as legacy product erodes.\n- Cash $162.6M at Q1 close with a guided ~2-year runway, reducing the dilution overhang that usually caps sub-$2 biotech.\n- Analyst consensus Strong Buy, average price target ~$4.20; HC Wainwright reiterated Buy at $6 on 2026-07-01 — roughly 3.4x–5x current.\n\n## Bear Case\n- The market did not re-rate on VOICE and has decayed since: from ~$1.40 in mid-July to ~$1.22 on 2026-07-24, pinned in the bottom decile of the $0.823–$4.010 range. Positive science into a rolled-over chart is a value-trap configuration.\n- Rating downgrade (Seeking Alpha, 2026-07-14): profitability remains distant amid Auryxia's decline and rising costs; the 45–55% discount to peers reads as execution risk priced in, not obvious mispricing.\n- Guidance drifting the wrong way: 2026 revenue estimate cut from $222.5M to $206.6M and FY loss widened from ~$0.056 to ~$0.17 per share heading into the print.\n- Total revenue is shrinking: Q1 2026 $53.5M vs $57.3M in Q1 2025 (-6.6%) as legacy Auryxia (ferric citrate) erosion offsets Vafseo growth; net loss widened to $9.1M.\n- 2027 ESRD PPS bundle entry plus TDAPA expiry compresses reimbursement and net pricing — the structural cliff capping any re-rate regardless of trial data.\n- VOICE next steps are vague: full dataset promised to an undated scientific meeting, with no label change, guideline update, or timeline commitment. Outcomes data is not the same as booked revenue.\n- Micro-cap ~$327M, unprofitable, thin liquidity and little institutional sponsorship — no anchored bid to hold the stock between catalysts.\n\n## Setup & Price Structure\n- ~$1.22 (2026-07-24), 52-week range $0.823–$4.010 — roughly 48% below the $4.01 high and only ~48% above the $0.82 low, sitting in the lower band with a downward slope over the past two weeks.\n- A positive binary fired (VOICE) and price failed to hold any breakout, then leaked lower — the momentum confirmation an accelerating-narrative entry requires is absent.\n- Base support sits near $1.10–$1.15; a hold there keeps the post-VOICE floor intact, while a break reopens the $0.82 low. A fresh long needs price to reclaim structure on volume and prove the outcomes data is being absorbed. At current levels that confirmation does not exist, so any entry ahead of it is buying a cheap chart rather than a trend.\n\n## Catalyst Calendar (next 30 days)\n\n- 2H26 (undated): potential DaVita protocol adoption — the largest single upside swing factor for the patient base.\n- Undated scientific meeting: full VOICE dataset presentation — a secondary catalyst with no set date.\n\n## Elapsed catalysts\n\n- ~2026-07-30 to 2026-08-06 (Q2 2026 earnings, after close; vendors split on the exact day — one lists 2026-07-30, another 2026-08-06): commercial-ramp binary. Watch Vafseo net revenue (sequential vs the $15.8M Q1 base), patient/prescriber adds, cash burn against the $162.6M balance, and any large dialysis-organization / DaVita commentary. Fresh entries into the print carry binary risk; standing aside until it clears is the disciplined stance. *(passed 3d ago)*\n\n## What Would Change Our Mind\n- Bullish flip: a Q2 print with Vafseo revenue re-accelerating (sequential growth holding above the ~$15.8M base) plus a concrete DaVita or large-DO adoption signal, AND price reclaiming ~$1.60 on expanding volume — that converts the show-me story into confirmation and justifies a real entry.\n- Bearish confirmation: a weekly close below $1.15 loses the post-VOICE base and reopens the $0.82 52-week low; a Q2 print showing Vafseo decelerating with another guidance cut hardens the value-trap read.\n- Theme flip: precision-biotech-therapeutics rotating toward saturated with no DaVita catalyst leaves this dead money into the 2027 bundle cliff.\n\n## Correlation Notes\n- Idiosyncratic and catalyst-driven, not sector-beta: the stock moves on VOICE, the Q2 print, and reimbursement policy rather than broad biotech, so XBI up-days do little for it beyond general risk-on liquidity for sub-$2 names.\n- Reimbursement-policy sensitive: CMS ESRD PPS bundle rules and TDAPA timing drive the structural story more than clinical peers do — the 2027 transition is the dominant macro variable.\n- Peer read-through runs through the HIF-PHI class and dialysis-organization anemia-protocol behavior (USRC, DaVita, Fresenius), not large-cap pharma; a competitor protocol shift or a rival HIF-PHI datapoint would move the narrative faster than any index.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-07-26T11:31:21+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}